Reorganization Is Unifying Theme of CDER FY2005 Report
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CDER highlights the web of organizational changes it has made in response to challenges ranging from drug safety to slow reviews and shrinking pipelines in the Center’s annual fiscal year Report to the Nation, released Aug. 18.
You may also be interested in...
Total NDA/BLA, New Use Approvals Recovered As NMEs Slowed – CDER Report
The declining trend in approval of new molecular entities has not been replicated in reviews of follow-on compounds, new formulations, and new uses, CDER's 2005 Report to the Nation suggests
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011